PD-1 blockade with its corresponding monoclonal antibodies (mAbs) is remarkably effective against advanced melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) (Routy et al. 2018). The gene discussed is PDCD1; the disease is melanoma.